UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz, Ph.D., as vice president of operations
- UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz, Ph.D., as vice president of operations
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Przemyslaw (Mike) Sapieha, Ph.D., as chief scientific advisor. - Mike is a long-term UNITY collaborator and an outstanding scientist whose work on the biological pathways impacting age-related eye diseases has been instrumental in the advancement of our Bcl-xL inhibitor, UBX1325, into the clinic, said Anirvan Ghosh, Ph.D., chief executive officer of UNITY.
- I am looking forward to joining Anirvan and the UNITY team to contribute to the realization of that vision.
- I am pleased to welcome Mike, Jason, and Nate to our leadership team as we drive UNITY forward.